SCHEMBL4470641

SCHEMBL4470641

Fc1ccc(N(c2cccc(Cl)n2)C(c2cccnc2)c2cccnc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.37
CYP19A1 P11511 1/20 0.36
KCNA5 P22460 7/20 0.35
KCND3 Q9UK17 2/20 0.35
KCNE1 P15382 1/20 0.35
KCNQ1 P51787 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CFTR P13569 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
GOPC Q9HD26 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
HTT P42858 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
KCNH2 Q12809 1/20 0.31
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4462104 0.88 CFTR (0.42) CYP19A1KCNA5CFTRSLC6A2SLC6A4
SCHEMBL4461625 0.87 CYP19A1 (0.40) CYP19A1KCNA5KCND3L3MBTL1CFTR
SCHEMBL4458360 0.85 POLB (0.37) POLBCYP19A1KCNA5KCND3KCNE1
SCHEMBL14435390 0.84 CYP19A1 (0.38) CYP19A1KCNA5KCND3L3MBTL1CFTR
SCHEMBL4458972 0.83 CFTR (0.41) CYP19A1KCNA5CFTRSLC6A2SLC6A4
SCHEMBL4472006 0.81 POLB (0.38) POLBKCNA5KCND3KCNE1KCNQ1
SCHEMBL4459564 0.80 CYP19A1 (0.36) CYP19A1KCNA5MEN1KMT2A
SCHEMBL4469178 0.79 POLB (0.41) POLBKCNA5KCND3KCNE1KCNQ1
SCHEMBL14435382 0.79 KCNA5 (0.39) POLBKCNA5KCND3KCNE1KCNQ1
SCHEMBL4456765 0.78 POLB (0.42) POLBKCNA5KCND3KCNE1KCNQ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030043-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-01-29 US claimed
EP-1981507-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2008-10-22 EP claimed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO claimed
US-20090030043-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
EP-1981507-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2008-10-22 EP disclosed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030043-A1 Potassium Channel Inhibitors KCNJ2, KCNH2, KCNH3 POLB 4703/4885CYP19A1 4359/4885KCNA5 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.